We are live on ! Find out more
JSPR icon

Jasper Therapeutics

59 hedge funds and large institutions have $380M invested in Jasper Therapeutics in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

885% more capital inflows, than outflows

Capital inflows: $101M | Capital outflows: $10.3M

399% more call options, than puts

Call options by funds: $4.27M | Put options by funds: $855K

217% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 6

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

136% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 14

48% more funds holding

Funds holding: 40 → 59 (+19)

13.1% more ownership

Funds ownership: 73.41% → 86.51% (+13%)

Holders
59
Holders Change
+19
Holders Change %
+47.5%
% of All Funds
0.85%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.09%
New
33
Increased
19
Reduced
6
Closed
14
Calls
$4.27​M
Puts
$855​K
Net Calls
+$3.41​M
Net Calls Change
+$455​K

JSPR Hedge Fund Activity: Q1 2024 in Review

59 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2024, worth a combined $380M — up 493% from $64.1M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new JSPR positions and 14 closed out — a net gain of 19 holders — while 19 added to existing stakes and 6 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $13.5M. The largest seller was Sphera Funds Management, cutting an estimated $3.69M.

  • 59 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2024, up from 40 in Q4 2023.
  • Funds reported $380M of Jasper Therapeutics stock for Q1 2024, up 493% quarter-over-quarter.
  • 33 funds opened new Jasper Therapeutics positions in Q1 2024 and 14 closed out, a net change of +19 holders.
  • The largest Jasper Therapeutics buyer in Q1 2024 was Avidity Partners Management, an estimated $13.5M added.
  • The largest Jasper Therapeutics seller in Q1 2024 was Sphera Funds Management, an estimated $3.69M sold.

Based on aggregated 13F filings for Q1 2024.